- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00002987
Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's Disease
Minimal Initial Therapy (MIT) for "Early" Supradiaphragmatic Hodgkin's Disease: A Multicenter Randomized Trial of Short Neoadjuvant Chemotherapy (VAPEC-B) Plus Involved Field Radiotherapy (MIT) Versus Mantle Radiotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells.
PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy plus radiation therapy with radiation therapy alone in treating patients with early-stage Hodgkin's disease.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
OBJECTIVES: I. Determine the recurrence rate and long term survival of patients with early stage Hodgkin's disease given vincristine/doxorubicin/prednisolone/ etoposide/cyclophosphamide/bleomycin (VAPEC-B) chemotherapy and involved field radiation vs mantle radiotherapy.
OUTLINE: This is a randomized multicenter study. Patients are randomized to receive either vincristine/doxorubicin/prednisolone/etoposide/cyclophosphamide/ bleomycin (VAPEC-B) chemotherapy and involved field radiotherapy or mantle radiotherapy only. Patients receiving VAPEC-B are given prednisolone daily on weeks 1-6, doxorubicin IV along with cyclophosphamide IV on week 1, doxorubicin IV and etoposide orally for 5 days on week 3, and vincristine and bleomycin IV on weeks 2 and 4. Involved field radiotherapy is commenced at week 6, within 14 to 21 days of the last chemotherapy treatment. Patients randomized to receive mantle radiotherapy only are given treatments daily for 4 weeks. Patients are followed every 3 months for the first two years, every 4 months for the third year, every 6 months for the fourth and fifth years and annually thereafter.
PROJECTED ACCRUAL: 400 patients will be accrued over 4-5 years.
Studietype
Registrering (Forventet)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
Preston, Storbritannia, PR2 9HT
- Royal Preston Hospital
-
-
England
-
Birmingham, England, Storbritannia, B15 2TT
- University Birmingham
-
Bristol, England, Storbritannia, BS2 8ED
- Bristol Oncology Centre
-
Bristol, England, Storbritannia, BS2 8BJ
- Bristol Royal Hospital for Sick Children
-
Cambridge, England, Storbritannia, CB2 2QQ
- Addenbrooke's NHS Trust
-
Derby, England, Storbritannia, DE1 2QY
- Derbyshire Royal Infirmary
-
Leeds, England, Storbritannia, LS16 6QB
- Cookridge Hospital
-
Leicester, England, Storbritannia, LE1 5WW
- University Hospitals of Leicester
-
London, England, Storbritannia, W1G 3AA
- Middlesex Hospital- Meyerstein Institute
-
Merseyside, England, Storbritannia, L63 4JY
- Clatterbridge Centre for Oncology NHS Trust
-
Newcastle Upon Tyne, England, Storbritannia, NE4 6BE
- Newcastle General Hospital
-
Northwood, England, Storbritannia, HA6 2RN
- Mount Vernon Hospital
-
Norwich, England, Storbritannia, NR1 3SR
- Norfolk & Norwich Hospital
-
Oxford, England, Storbritannia, 0X3 9DU
- Oxford Radcliffe Hospital
-
Sutton, England, Storbritannia, SM2 5PT
- Royal Marsden Hospital
-
Westcliff-On-Sea, England, Storbritannia
- Southend General Hospital
-
-
Scotland
-
Edinburgh, Scotland, Storbritannia
- Royal Hospital for Sick Children
-
-
-
-
-
Cape Town, Sør-Afrika, 7925
- Groote Schuur Hospital, Cape Town
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
DISEASE CHARACTERISTICS: Histologically proven stage IA or IIA Hodgkin's disease without mediastinal bulk Patients with Hodgkin's disease existing below diaphragm only are not eligible
PATIENT CHARACTERISTICS: Age: 16 to 75 Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Not HIV positive No prior malignancy other than basal cell carcinoma or cervical intraepithelial neoplasia
PRIOR CONCURRENT THERAPY: No prior treatment
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studiestol: Michael Williams, MD, Cambridge University Hospitals NHS Foundation Trust
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Radford JA, Williams MV, Hancock BW, et al.: Minimal initial chemotherapy plus involved field radiotherapy (RT) vs. mantle field RT for clinical stage IA/IIA supra-diaphragmatic Hodgkin's disease (HD). Results of the UK Lymphoma Group LY07 trial. [Abstract] Eur J Haematol 73 (Suppl 65): A-E08, 39, 2004.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Lymfesykdommer
- Immunproliferative lidelser
- Lymfom
- Hodgkins sykdom
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Enzymhemmere
- Anti-inflammatoriske midler
- Antirevmatiske midler
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Tubulin modulatorer
- Antimitotiske midler
- Mitosemodulatorer
- Glukokortikoider
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Antineoplastiske midler, hormonelle
- Antineoplastiske midler, Alkylering
- Alkyleringsmidler
- Myeloablative agonister
- Antineoplastiske midler, fytogene
- Topoisomerase II-hemmere
- Topoisomerasehemmere
- Antibiotika, antineoplastisk
- Prednisolon
- Cyklofosfamid
- Etoposid
- Doxorubicin
- Liposomal doksorubicin
- Vincristine
- Bleomycin
Andre studie-ID-numre
- CDR0000065522
- MRC-UKLG-LY07
- EU-97004
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .